Table 1 Baseline characteristics of the study population
|  | No psoriasis | Mild psoriasis | Severe psoriasis | p–value |
|---|---|---|---|---|
| Â | n=51,752 | n=1074 | n=315 | Â |
Male (%) | 36,989 (71.5) | 767 (71.4) | 193 (61.3) | 0.003 |
Female (%) | 14,763 (28.5) | 307 (28.6) | 122 (38.7) | Â |
Age, years (SD) | 65.1 (11.6) | 65.0 (10.7) | 63.5 (10.9) | 0.06 |
Treatment (%) | Â | Â | Â | Â |
  Beta-blocker | 20,851 (40.3) | 434 (40.4) | 132 (41.9) | 0.60 |
  ACE inhibitor/ARB | 16,868 (32.6) | 381 (35.5) | 121 (38.4) | 0.003 |
  Statin | 21,462 (41.5) | 506 (47.1) | 136 (43.2) | 0.003 |
  Platelet inhibitor | 21,209 (41.0) | 490 (45.6) | 133 (42.2) | 0.02 |
  Loop diuretic | 6663 (12.9) | 139 (12.9) | 48 (15.2) | 0.33 |
  Spironolactone | 1733 (3.4) | 38 (3.5) | 11 (3.5) | 0.74 |
  Vitamin K antagonist | 2505 (4.8) | 48 (4.5) | 11 (3.5) | 0.23 |
  Glucose lowering medication | 5734 (11.1) | 123 (11.5) | 52 (16.5) | 0.01 |
  NSAID | 3465 (6.7) | 101 (9.4) | 36 (11.4) | <0.001 |
  Antidepressive medication | 4569 (8.8) | 125 (11.6) | 42 (13.3) | <0.001 |
Comorbidity (%) | Â | Â | Â | Â |
  Myocardial infarction | 31,078 (60.1) | 596 (55.5) | 182 (60.0) | 0.008 |
  Cardiac dysrhythmia | 4759 (9.2) | 115 (10.7) | 28 (3.2) | 0.33 |
  Diabetes with complications | 2117 (4.1) | 38 (3.5) | 22 (7.0) | 0.20 |
  Cerebrovascular disease | 1373 (2.7) | 33 (3.1) | 10 (3.2) | 0.32 |
  Pulmonary edema | 187 (0.4) | 5 (0.5) | 2 (0.6) | 0.33 |
  Shock | 593 (1.2) | 6 (0.6) | 8 (2.5) | 0.62 |
  Cancer | 424 (0.8) | 9 (0.8) | 3 (1.0) | 0.62 |
  Acute renal failure | 331 (0.6) | 2 (0.2) | 3 (1.0) | 0.46 |
  Chronic renal failure | 592 (1.1) | 8 (0.2) | 4 (1.1) | 0.51 |
  Chronic renal failure | 1904 (3.7) | 50 (4.7) | 15 (4.8) | 0.06 |
  pulmonary disease |  |  |  |  |